{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:43:46Z","timestamp":1793454226218,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155 RESIST, Project 390874280"],"award-info":[{"award-number":["EXC 2155 RESIST, Project 390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"],"award-info":[{"award-number":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"],"award-info":[{"award-number":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"],"award-info":[{"award-number":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"],"award-info":[{"award-number":["EXC 2155 \u201cRESIST\u201d \u2013 Project ID 390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2155 RESIST_390874280"],"award-info":[{"award-number":["EXC2155 RESIST_390874280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010570","name":"Nieders\u00e4chsisches Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["INDIRA 11-76251-99-6\/19 (ZN3437)"],"award-info":[{"award-number":["INDIRA 11-76251-99-6\/19 (ZN3437)"]}],"id":[{"id":"10.13039\/501100010570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["OPTIS, Project ID 9B811"],"award-info":[{"award-number":["OPTIS, Project ID 9B811"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["OPTIS, Project ID 9B811"],"award-info":[{"award-number":["OPTIS, Project ID 9B811"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["OPTIS, Project ID 9B811"],"award-info":[{"award-number":["OPTIS, Project ID 9B811"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["OPTIS, ID9B811"],"award-info":[{"award-number":["OPTIS, ID9B811"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helmholtz International Lab for anti-infectives"},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["DZIF, TTU 09.719"],"award-info":[{"award-number":["DZIF, TTU 09.719"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011937","name":"Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur","doi-asserted-by":"publisher","award":["INDIRA 11-76251-99-6\/19 (ZN3437)"],"award-info":[{"award-number":["INDIRA 11-76251-99-6\/19 (ZN3437)"]}],"id":[{"id":"10.13039\/100011937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC<jats:sub>50<\/jats:sub>: 10-118\u2009nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.<\/jats:p>","DOI":"10.1038\/s41467-024-45241-y","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T07:02:10Z","timestamp":1707375730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor"],"prefix":"10.1038","volume":"15","author":[{"given":"Svenja M.","family":"Sake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Rajak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-9011","authenticated-orcid":false,"given":"Melanie","family":"Urbanek-Quaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-4689","authenticated-orcid":false,"given":"Arnaud","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia P.","family":"Gunesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Grethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Matthaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"R\u00fcckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Galloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-3190","authenticated-orcid":false,"given":"Thibaut","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-0064","authenticated-orcid":false,"given":"Ronan","family":"Le Goffic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortune","family":"Hontonnou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab K.","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0788-7217","authenticated-orcid":false,"given":"Kristen","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaycie","family":"Morwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-1384","authenticated-orcid":false,"given":"Katharina","family":"Rox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-4568","authenticated-orcid":false,"given":"Walid A. M.","family":"Elgaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3480-7115","authenticated-orcid":false,"given":"Jiabin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"El\u00e9ou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-3856","authenticated-orcid":false,"given":"Marie-Anne","family":"Rameix-Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-4663","authenticated-orcid":false,"given":"Anna K. H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-5830","authenticated-orcid":false,"given":"Martin","family":"Empting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-2953","authenticated-orcid":false,"given":"Chris","family":"Lauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-5345","authenticated-orcid":false,"given":"Thomas F.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-7241","authenticated-orcid":false,"given":"Thomas","family":"Krey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-3097","authenticated-orcid":false,"given":"Sibylle","family":"Haid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-4422","authenticated-orcid":false,"given":"Thomas","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"45241_CR1","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","volume":"388","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 388, 3027\u20133035 (2016).","journal-title":"Lancet"},{"key":"45241_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","volume":"3","author":"NI Mazur","year":"2015","unstructured":"Mazur, N. I. et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir. Med 3, 888\u2013900 (2015).","journal-title":"Lancet Respir. Med"},{"key":"45241_CR3","first-page":"561","volume":"118","author":"M Lange","year":"2021","unstructured":"Lange, M. et al. Non-Appearance of the RSV Season 2020\/21 During the COVID-19 Pandemic-Prospective, Multicenter Data on the Incidence of Respiratory Syncytial Virus (RSV) Infection. Dtsch Arztebl Int. 118, 561\u2013562 (2021).","journal-title":"Dtsch Arztebl Int."},{"key":"45241_CR4","doi-asserted-by":"publisher","first-page":"100807","DOI":"10.1016\/j.eclinm.2021.100807","volume":"34","author":"M Haapanen","year":"2021","unstructured":"Haapanen, M., Renko, M., Artama, M. & Kuitunen, I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children\u2014A nationwide register study in Finland. EClinicalMedicine 34, 100807 (2021).","journal-title":"EClinicalMedicine"},{"key":"45241_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(22)00525-4","volume":"23","author":"M Bardsley","year":"2023","unstructured":"Bardsley, M. et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 23, 56\u201366 (2023).","journal-title":"Lancet Infect Dis"},{"key":"45241_CR6","doi-asserted-by":"crossref","first-page":"2100639","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100639","volume":"26","author":"J van Summeren","year":"2021","unstructured":"van Summeren, J. et al. Low levels of respiratory syncytial virus activity in Europe during the 2020\/21 season: what can we expect in the coming summer and autumn\/winter? Eur. Surveill. 26, 2100639 (2021).","journal-title":"Eur. Surveill."},{"key":"45241_CR7","doi-asserted-by":"publisher","first-page":"2100630","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100630","volume":"26","author":"JS Casalegno","year":"2021","unstructured":"Casalegno, J. S. et al. Characteristics of the delayed respiratory syncytial virus epidemic, 2020\/2021, Rhone Loire, France. Eur. Surveill. 26, 2100630 (2021).","journal-title":"Eur. Surveill."},{"key":"45241_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1473-3099(22)00763-0","volume":"23","author":"G den Hartog","year":"2023","unstructured":"den Hartog G, et al. Decline of RSV-specific antibodies during the COVID-19 pandemic. Lancet Infect Dis. 23, 23\u201325 (2023).","journal-title":"Lancet Infect Dis"},{"key":"45241_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40121-022-00737-2","volume":"12","author":"D Pinquier","year":"2023","unstructured":"Pinquier, D. et al. Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities. Infect. Dis. Ther. 12, 317\u2013332 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"45241_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1086\/653534","volume":"51","author":"O Adams","year":"2010","unstructured":"Adams, O. et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 51, 185\u2013188 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"45241_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00734-7","volume":"8","author":"TJ Ruckwardt","year":"2023","unstructured":"Ruckwardt, T. J. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines 8, 138 (2023).","journal-title":"NPJ Vaccines"},{"key":"45241_CR12","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","volume":"62","author":"GS Cockerill","year":"2019","unstructured":"Cockerill, G. S., Good, J. A. D. & Mathews, N. State of the art in respiratory syncytial virus drug discovery and development. J. Med. Chem. 62, 3206\u20133227 (2019).","journal-title":"J. Med. Chem."},{"key":"45241_CR13","doi-asserted-by":"crossref","unstructured":"Alpana Waghmare JAE. 21\u2014Respiratory viruses. Pediatric Transplant and Oncology Infectious Diseases. Ch. 21, 148-154.e143, (2021).","DOI":"10.1016\/B978-0-323-64198-2.00030-0"},{"key":"45241_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40121-020-00383-6","volume":"10","author":"JB Domachowske","year":"2021","unstructured":"Domachowske, J. B., Anderson, E. J. & Goldstein, M. The future of respiratory syncytial virus disease prevention and treatment. Infect. Dis. Ther. 10, 47\u201360 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"45241_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41586-021-03703-z","volume":"595","author":"J Risso-Ballester","year":"2021","unstructured":"Risso-Ballester, J. et al. A condensate-hardening drug blocks RSV replication in vivo. Nature 595, 596\u2013599 (2021).","journal-title":"Nature"},{"key":"45241_CR16","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1810137115","volume":"115","author":"J Janes","year":"2018","unstructured":"Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl. Acad. Sci. USA 115, 10750\u201310755 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45241_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"L Riva","year":"2020","unstructured":"Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113\u2013119 (2020).","journal-title":"Nature"},{"key":"45241_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1401184","volume":"371","author":"JP DeVincenzo","year":"2014","unstructured":"DeVincenzo, J. P. et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 371, 711\u2013722 (2014).","journal-title":"N. Engl. J. Med."},{"key":"45241_CR19","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1128\/AAC.00211-07","volume":"51","author":"J Chapman","year":"2007","unstructured":"Chapman, J. et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51, 3346\u20133353 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45241_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2174\/1389557518666180801110342","volume":"18","author":"S Bagchi","year":"2018","unstructured":"Bagchi, S., Rathee, P., Jayaprakash, V. & Banerjee, S. Farnesyl transferase inhibitors as potential anticancer agents. Mini Rev. Med. Chem. 18, 1611\u20131623 (2018).","journal-title":"Mini Rev. Med. Chem."},{"key":"45241_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Lonafarnib: First Approval. Drugs 81, 283\u2013289 (2021).","journal-title":"Drugs"},{"key":"45241_CR22","doi-asserted-by":"publisher","first-page":"e1002331","DOI":"10.1371\/journal.ppat.1002331","volume":"7","author":"S Pfefferle","year":"2011","unstructured":"Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).","journal-title":"PLoS Pathog."},{"key":"45241_CR23","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1128\/JVI.03074-15","volume":"90","author":"S Haid","year":"2015","unstructured":"Haid, S., Grethe, C., Bankwitz, D., Grunwald, T. & Pietschmann, T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system. J. Virol. 90, 3065\u20133073 (2015).","journal-title":"J. Virol."},{"key":"45241_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","volume":"48","author":"C Cianci","year":"2004","unstructured":"Cianci, C. et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48, 413\u2013422 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45241_CR25","doi-asserted-by":"publisher","first-page":"E3441","DOI":"10.1073\/pnas.1405198111","volume":"111","author":"D Yan","year":"2014","unstructured":"Yan, D. et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc. Natl Acad. Sci. USA 111, E3441\u2013E3449 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45241_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/infdis\/jiq100","volume":"203","author":"Q Zhu","year":"2011","unstructured":"Zhu, Q. et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab. J. Infect. Dis. 203, 674\u2013682 (2011).","journal-title":"J. Infect. Dis."},{"key":"45241_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nchembio.1982","volume":"12","author":"MB Battles","year":"2016","unstructured":"Battles, M. B. et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat. Chem. Biol. 12, 87\u201393 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"45241_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1465-9921-14-135","volume":"14","author":"MS Walters","year":"2013","unstructured":"Walters, M. S. et al. Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir. Res. 14, 135 (2013).","journal-title":"Respir. Res."},{"key":"45241_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6104","volume":"5","author":"MA Rameix-Welti","year":"2014","unstructured":"Rameix-Welti, M. A. et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat. Commun. 5, 5104 (2014).","journal-title":"Nat. Commun."},{"key":"45241_CR30","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1021\/cr900021w","volume":"109","author":"L Hedstrom","year":"2009","unstructured":"Hedstrom, L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem. Rev. 109, 2903\u20132928 (2009).","journal-title":"Chem. Rev."},{"key":"45241_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2017.11.004","volume":"149","author":"X Tong","year":"2018","unstructured":"Tong, X. et al. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antivir. Res. 149, 34\u201340 (2018).","journal-title":"Antivir. Res."},{"key":"45241_CR32","doi-asserted-by":"publisher","first-page":"109305","DOI":"10.1016\/j.biopha.2019.109305","volume":"118","author":"G Mei-Jiao","year":"2019","unstructured":"Mei-Jiao, G. et al. Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. Biomed. Pharmacother. 118, 109305 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"45241_CR33","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","volume":"44","author":"W Markland","year":"2000","unstructured":"Markland, W., McQuaid, T. J., Jain, J. & Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44, 859\u2013866 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45241_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18, 345\u2013360 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"45241_CR35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbamcr.2011.11.007","volume":"1823","author":"R Geller","year":"2012","unstructured":"Geller, R., Taguwa, S. & Frydman, J. Broad action of Hsp90 as a host chaperone required for viral replication. Biochim Biophys. Acta 1823, 698\u2013706 (2012).","journal-title":"Biochim Biophys. Acta"},{"key":"45241_CR36","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00705-017-3511-1","volume":"162","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. HSP90: a promising broad-spectrum antiviral drug target. Arch. Virol. 162, 3269\u20133282 (2017).","journal-title":"Arch. Virol."},{"key":"45241_CR37","doi-asserted-by":"publisher","first-page":"9366","DOI":"10.3390\/ijms22179366","volume":"22","author":"A Lubkowska","year":"2021","unstructured":"Lubkowska, A., Pluta, W., Stronska, A. & Lalko, A. Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection. Int J. Mol. Sci. 22, 9366 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"45241_CR38","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1074\/mcp.M110.001651","volume":"9","author":"A Radhakrishnan","year":"2010","unstructured":"Radhakrishnan, A. et al. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol. Cell Proteom. 9, 1829\u20131848 (2010).","journal-title":"Mol. Cell Proteom."},{"key":"45241_CR39","doi-asserted-by":"publisher","first-page":"e56762","DOI":"10.1371\/journal.pone.0056762","volume":"8","author":"R Geller","year":"2013","unstructured":"Geller, R., Andino, R. & Frydman, J. Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus. PLoS One 8, e56762 (2013).","journal-title":"PLoS One"},{"key":"45241_CR40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cbpa.2010.03.019","volume":"14","author":"JR Porter","year":"2010","unstructured":"Porter, J. R., Fritz, C. C. & Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 14, 412\u2013420 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"45241_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/or.2022.8443","volume":"49","author":"ZN Li","year":"2023","unstructured":"Li, Z. N. & Luo, Y. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol. Rep. 49, 6 (2023).","journal-title":"Oncol. Rep."},{"key":"45241_CR42","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.73.9.7262-7270.1999","volume":"73","author":"MK Pastey","year":"1999","unstructured":"Pastey, M. K., Crowe, J. E. Jr. & Graham, B. S. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J. Virol. 73, 7262\u20137270 (1999).","journal-title":"J. Virol."},{"key":"45241_CR43","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1128\/JVI.79.9.5326-5336.2005","volume":"79","author":"TL Gower","year":"2005","unstructured":"Gower, T. L. et al. RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J. Virol. 79, 5326\u20135336 (2005).","journal-title":"J. Virol."},{"key":"45241_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/viro.2001.0891","volume":"283","author":"TL Gower","year":"2001","unstructured":"Gower, T. L., Peeples, M. E., Collins, P. L. & Graham, B. S. RhoA is activated during respiratory syncytial virus infection. Virology 283, 188\u2013196 (2001).","journal-title":"Virology"},{"key":"45241_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/71503","volume":"6","author":"MK Pastey","year":"2000","unstructured":"Pastey, M. K., Gower, T. L., Spearman, P. W., Crowe, J. E. Jr. & Graham, B. S. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat. Med 6, 35\u201340 (2000).","journal-title":"Nat. Med"},{"key":"45241_CR46","first-page":"363","volume":"13","author":"PA Solski","year":"2002","unstructured":"Solski, P. A., Helms, W., Keely, P. J., Su, L. & Der, C. J. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ. 13, 363\u2013373 (2002).","journal-title":"Cell Growth Differ."},{"key":"45241_CR47","doi-asserted-by":"publisher","first-page":"e1005318","DOI":"10.1371\/journal.ppat.1005318","volume":"11","author":"SM Johnson","year":"2015","unstructured":"Johnson, S. M. et al. Respiratory Syncytial Virus Uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 11, e1005318 (2015).","journal-title":"PLoS Pathog."},{"key":"45241_CR48","doi-asserted-by":"publisher","first-page":"e0001021","DOI":"10.1128\/JVI.00010-21","volume":"95","author":"G Green","year":"2021","unstructured":"Green, G. et al. CX3CR1 is a receptor for human respiratory syncytial virus in cotton rats. J. Virol. 95, e0001021 (2021).","journal-title":"J. Virol."},{"key":"45241_CR49","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/cid\/ciz1166","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly, R. F. et al. A Phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin. Infect. Dis. 71, 2777\u20132786 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"45241_CR50","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/cid\/ciz1167","volume":"71","author":"FM Marty","year":"2020","unstructured":"Marty, F. M. et al. A Phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. Clin. Infect. Dis. 71, 2787\u20132795 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"45241_CR51","doi-asserted-by":"publisher","first-page":"e02312","DOI":"10.1128\/AAC.02312-19","volume":"64","author":"DP Porter","year":"2020","unstructured":"Porter, D. P. et al. Assessment of Drug Resistance during Phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus. Antimicrob. Agents Chemother. 64, e02312\u2013e02319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45241_CR52","first-page":"49","volume":"57","author":"E Groaz","year":"2021","unstructured":"Groaz, E., De Clercq, E. & Herdewijn, P. Anno 2021: Which antivirals for the coming decade? Annu Rep. Med Chem. 57, 49\u2013107 (2021).","journal-title":"Annu Rep. Med Chem."},{"key":"45241_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/hep4.1043","volume":"1","author":"L Canini","year":"2017","unstructured":"Canini, L. et al. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatol. Commun. 1, 288\u2013292 (2017).","journal-title":"Hepatol. Commun."},{"key":"45241_CR54","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","volume":"76","author":"KJ Blight","year":"2002","unstructured":"Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001\u201313014 (2002).","journal-title":"J. Virol."},{"key":"45241_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2017.09.006","volume":"147","author":"P Behrendt","year":"2017","unstructured":"Behrendt, P. et al. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antivir. Res. 147, 19\u201328 (2017).","journal-title":"Antivir. Res."},{"key":"45241_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-2438-7_8","volume":"1282","author":"HR Jonsdottir","year":"2015","unstructured":"Jonsdottir, H. R. & Dijkman, R. Characterization of human coronaviruses on well-differentiated human airway epithelial cell cultures. Methods Mol. Biol. 1282, 73\u201387 (2015).","journal-title":"Methods Mol. Biol."},{"key":"45241_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"45241_CR58","doi-asserted-by":"publisher","first-page":"e1000762","DOI":"10.1371\/journal.ppat.1000762","volume":"6","author":"T Krey","year":"2010","unstructured":"Krey, T. et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6, e1000762 (2010).","journal-title":"PLoS Pathog."},{"key":"45241_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Xds. Acta Crystallogr D. Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"45241_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1107\/S0907444905036693","volume":"62","author":"P Evans","year":"2006","unstructured":"Evans, P. Scaling and assessment of data quality. Acta Crystallogr D. Biol. Crystallogr 62, 72\u201382 (2006).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"45241_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1107\/S2059798323003595","volume":"79","author":"J Agirre","year":"2023","unstructured":"Agirre, J. et al. The CCP4 suite: integrative software for macromolecular crystallography. Acta Crystallogr D. Struct. Biol. 79, 449\u2013461 (2023).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"45241_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nmeth.3211","volume":"12","author":"T Weinert","year":"2015","unstructured":"Weinert, T. et al. Fast native-SAD phasing for routine macromolecular structure determination. Nat. Methods 12, 131\u2013133 (2015).","journal-title":"Nat. Methods"},{"key":"45241_CR63","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr"},{"key":"45241_CR64","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"45241_CR65","unstructured":"Bricogne, G. BE. et al. Womack T.O. BUSTER.) (2017)."},{"key":"45241_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. Biol. Crystallogr 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"45241_CR67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1107\/S2059798316018210","volume":"73","author":"D Liebschner","year":"2017","unstructured":"Liebschner, D. et al. Polder maps: improving OMIT maps by excluding bulk solvent. Acta Crystallogr D. Struct. Biol. 73, 148\u2013157 (2017).","journal-title":"Acta Crystallogr D. Struct. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45241-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45241-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45241-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T11:03:28Z","timestamp":1707649408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45241-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45241"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45241-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SMS, SH, JR, TFS and TP disclose that they are authoring a patent application \u201cLONAFARNIB FOR USE IN THE TREATMENT OF VIRAL INFECTIONS\u201d describing lonafarnib as antiviral compound that inhibits RSV infection (21152993.8-1132). The authors declare no competing interests and no restrictions on the publication of data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1173"}}